About: The θ-defensin retrocyclin 101 inhibits TLR4- and TLR2-dependent signaling and protects mice against influenza infection

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: The θ-defensin retrocyclin 101 inhibits TLR4- and TLR2-dependent signaling and protects mice against influenza infection Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	The θ-defensin retrocyclin 101 inhibits TLR4- and TLR2-dependent signaling and protects mice against influenza infection
Creator	Garzino-Demo, Alfredo Lai, Wendy Lu, Wuyuan Prantner, Daniel Cole, Alexander Shirey, Kari Vogel, Stefanie
Source	Medline; PMC
abstract	Despite widespread use of annual influenza vaccines, seasonal influenza-associated deaths number in the thousands each year, in part because of exacerbating bacterial superinfections. Therefore, discovering additional therapeutic options would be a valuable aid to public health. Recently, TLR4 inhibition has emerged as a possible mechanism for protection against influenza-associated lethality and acute lung injury. Based on recent data showing that rhesus macaque θ-defensins could inhibit TLR4-dependent gene expression, we tested the hypothesis that a novel θ-defensin, retrocyclin (RC)-101, could disrupt TLR4-dependent signaling and protect against viral infection. In this study, RC-101, a variant of the humanized θ-defensin RC-1, blocked TLR4-mediated gene expression in mouse and human macrophages in response to LPS, targeting both MyD88- and TRIF-dependent pathways. In a cell-free assay, RC-101 neutralized the biologic activity of LPS at doses ranging from 0.5 to 50 EU/ml, consistent with data showing that RC-101 binds biotinylated LPS. The action of RC-101 was not limited to the TLR4 pathway because RC-101 treatment of macrophages also inhibited gene expression in response to a TLR2 agonist, Pam3CSK4, but failed to bind that biotinylated agonist. Mouse macrophages infected in vitro with mouse-adapted A/PR/8/34 influenza A virus (PR8) also produced lower levels of proinflammatory cytokine gene products in a TLR4-independent fashion when treated with RC-101. Finally, RC-101 decreased both the lethality and clinical severity associated with PR8 infection in mice. Cumulatively, our data demonstrate that RC-101 exhibits therapeutic potential for the mitigation of influenza-related morbidity and mortality, potentially acting through TLR-dependent and TLR-independent mechanisms.
has issue date	2017-07-20(xsd:dateTime)
bibo:doi	10.1189/jlb.2a1215-567rr
bibo:pmid	28729359
has license	bronze-oa
sha1sum (hex)	757a89f247aa8746b8b2a661a073e401abd8a280
schema:url	https://doi.org/10.1189/jlb.2a1215-567rr
resource representing a document's title	The θ-defensin retrocyclin 101 inhibits TLR4- and TLR2-dependent signaling and protects mice against influenza infection
has PubMed Central identifier	PMC5597516
has PubMed identifier	28729359
schema:publication	Journal of Leukocyte Biology
resource representing a document's body	covid:757a89f247aa8746b8b2a661a073e401abd8a280#body_text
is schema:about of	named entity 'mechanisms' named entity 'human' named entity 'LPS.' named entity 'ranging' named entity 'vaccines' named entity 'gene' named entity 'agonist' named entity 'data' named entity 'lethality' named entity 'proinflammatory cytokine' named entity 'humanized' named entity 'consistent' named entity 'gene' named entity 'number' named entity 'TLR4' named entity 'products' named entity 'mechanism' named entity 'signaling' named entity 'Therefore' named entity 'expression' named entity 'gene' named entity 'viral infection' named entity 'lethality' named entity 'The action' named entity 'annual' named entity 'inhibits' named entity 'TLR4' named entity 'public health' named entity 'TRIF' named entity 'mice' named entity 'TLR4' named entity 'defensin' named entity 'macrophages' named entity 'influenza' named entity 'TLR2' named entity 'LPS' named entity 'viral infection' named entity 'inhibited' named entity 'mice' named entity 'TLR4' named entity 'proinflammatory' named entity 'Thermo Fisher' named entity 'solid-phase synthesis' named entity 'coimmunoprecipitation' named entity 'North America' named entity 'solid-phase peptide synthesis' named entity 'uridine' named entity 'lung' named entity 'membrane microdomains' named entity 'peptide' named entity 'LPS' named entity 'influenza infection' named entity '1-way ANOVA' named entity 'DMSO' named entity 'transfection' named entity 'influenza' named entity 'up-regulation' named entity 'LPS' named entity 'innate immune' named entity 'Laemmli' named entity 'MyD88' named entity 'infection' named entity 'Disulfide bonds' named entity 'RNA helicase' named entity 'Eritoran' named entity 'adaptor protein' named entity 'infection' named entity 'mice' named entity 'anti-inflammatory' named entity 'MyD88' named entity 'cytokine' named entity 'immune response' named entity 'HEK293T cells' named entity 'MyD88' named entity 'influenza'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software